Exelixis (EXEL) Shares Outstanding (Diluted Average) (2010 - 2026)
Exelixis (EXEL) recorded quarterly Shares Outstanding (Diluted Average) of $267.3 million in Q2 2026, down 5.16% quarter-over-quarter from $281.9 million in Q1 2026, and down 7.24% on a YoY basis from $288.2 million in Q2 2025.
Exelixis (EXEL) Shares Outstanding (Diluted Average) (2010 - 2026) Analysis & Trends
Exelixis' Shares Outstanding (Diluted Average) history runs 15 years deep, the most recent figure standing at $267.3 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Diluted Average) fell 7.24% year-over-year to $267.3 million; the TTM figure through Apr 2026 stood at $267.3 million (down 7.24% YoY), while the FY2026 annual figure was $281.9 million, down 4.82% from the prior year.
- Shares Outstanding (Diluted Average) was $267.3 million for Q2 2026 at Exelixis, down from $281.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $326.8 million in Q2 2023 to a low of $267.3 million in Q2 2026.
- Historically, Shares Outstanding (Diluted Average) has averaged $304.9 million across 5 years, with a median of $305.5 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) rose 0.92% in 2023, then dropped 10.11% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $324.6 million in 2022, then dropped by 0.95% to $321.5 million in 2023, then dropped by 9.33% to $291.5 million in 2024, then dropped by 4.44% to $278.5 million in 2025, then retreated by 4.03% to $267.3 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $267.3 million (Q2 2026), $281.9 million (Q1 2026), and $278.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 92.44 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 267.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 267.32 Mn |
| Jan 2, 2026 | 281.86 Mn |
| Oct 3, 2025 | 278.54 Mn |
| Jul 4, 2025 | 284.39 Mn |
| Apr 4, 2025 | 288.18 Mn |
| Jan 3, 2025 | 296.13 Mn |
| Sep 27, 2024 | 291.48 Mn |
| Jun 28, 2024 | 293.97 Mn |
| Mar 29, 2024 | 305.53 Mn |
| Dec 29, 2023 | 321.46 Mn |
| Sep 29, 2023 | 324.28 Mn |
| Jun 30, 2023 | 326.79 Mn |
| Mar 31, 2023 | 326.28 Mn |
| Dec 30, 2022 | 324.56 Mn |
| Sep 30, 2022 | 324.42 Mn |
| Jul 1, 2022 | 324.10 Mn |
| Apr 1, 2022 | 323.29 Mn |
| Dec 31, 2021 | 322.36 Mn |
| Oct 1, 2021 | 322.08 Mn |
| Jul 2, 2021 | 322.11 Mn |